SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

October 25, 2010 08:45 ET

Crystal Research Associates LLC Issues Executive Informational Overview® (EIO®) on Radient Pharmaceuticals

NEW YORK, NY--(Marketwire - October 25, 2010) -  Crystal Research Associates, LLC announced today it has issued an Executive Informational Overview® (EIO®) on Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC). The full 64-page report can be found at www.crystalra.com.

Radient Pharmaceuticals Corporation ("Radient" or "the Company") together with its wholly-owned subsidiary AMDL Diagnostics Inc. (ADI), is an in vitro (IVD) company commercializing Onko-Sure® (formerly DR-70®) -- a non-invasive, IVD test kit that detects and monitors up to 19 types of cancer. Onko-Sure® helps physicians answer important clinical questions related to early disease detection and progression in order ultimately to improve patient outcomes and survival. The distinctive feature of Radient's Onko-Sure® blood test is that it measures the accumulation of specific breakdown products in serum (blood) called fibrin and fibrinogen degradation products (FDPs). Research has found that FDP levels rise dramatically as cancer progresses. A potentially life-saving IVD cancer test, Onko-Sure® is currently cleared to monitor colorectal cancer (CRC) treatment/recurrence in the U.S.; to detect and monitor lung cancer in Canada; for use as a general cancer marker in Australia, Europe, India, Taiwan, and Vietnam; and for use in CRC patients in South Korea. Radient is working to obtain additional regulatory clearances for indications in the U.S. and abroad. Radient's subsidiary, ADI, operates research and development and quality control laboratories and an ISO 13485:2003-certified manufacturing facility for Onko-Sure® production.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical's current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

About Crystal Research Associates, LLC:
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small- and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of sixty-one thousand U.S. dollars and four hundred thousand, four-year warrants for its services in creating this report, for updates, and for printing costs.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323